RT @crisbergerot: PROMIS measures were briefer than BDI-II & CES-D but do not offer any advance in terms of diagnostic accuracy, reduced re…
RT @crisbergerot: PROMIS measures were briefer than BDI-II & CES-D but do not offer any advance in terms of diagnostic accuracy, reduced re…
Useful study 🤔 https://t.co/9JTcvLpFFk
RT @crisbergerot: PROMIS measures were briefer than BDI-II & CES-D but do not offer any advance in terms of diagnostic accuracy, reduced re…
RT @crisbergerot: PROMIS measures were briefer than BDI-II & CES-D but do not offer any advance in terms of diagnostic accuracy, reduced re…
RT @crisbergerot: PROMIS measures were briefer than BDI-II & CES-D but do not offer any advance in terms of diagnostic accuracy, reduced re…
RT @crisbergerot: PROMIS measures were briefer than BDI-II & CES-D but do not offer any advance in terms of diagnostic accuracy, reduced re…
RT @crisbergerot: PROMIS measures were briefer than BDI-II & CES-D but do not offer any advance in terms of diagnostic accuracy, reduced re…
RT @crisbergerot: PROMIS measures were briefer than BDI-II & CES-D but do not offer any advance in terms of diagnostic accuracy, reduced re…
PROMIS measures were briefer than BDI-II & CES-D but do not offer any advance in terms of diagnostic accuracy, reduced response burden or cost over other measures of #depression in #CancerPatients @sylviedlambert1 et al. #DistressScreening @cancer_stor
PROMIS depression measures briefer than BDI-II and CES-D but do not offer any advance in terms of diagnostic accuracy, reduced response burden or cost over other legacy measures of depression in oncology patients. https://t.co/s2prwB2Hum
PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients. https://t.co/PBeYioeCuS https://t.co/DNOM6YPkRs
#HealthEconJA PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients https://t.co/IBY4NBn9GQ